Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

View:
Post by DIprivateinvest on Jun 17, 2016 11:15am

IPSEN ?

Ipsen successfully issues inaugural €300 million 7-year Notes Paris (France) 9 June, 2016 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, announced today the successful issue of its inaugural unsecured 7-year Notes for a total of €300 million. These Notes mature on June 16, 2023 and pay interest at an annual rate of 1.875%. Application has been made for the Notes to be admitted to trading on the regulated market of Euronext Paris. Ipsen has been able to take advantage of the current market environment to raise long-term financing at attractive conditions. The transaction was well received by a diversified investor base and was more than 4 times over-subscribed, demonstrating the market’s confidence in Ipsen’s long-term business model. The purpose of this issue is to diversify and extend the maturity of Ipsen’s financial resources and to support its investment and business development strategy

Just reading through lines...
This maybe a hint. 

Any opinions? 
Comment by Biofinder on Jun 17, 2016 12:31pm
Ipsen is the logical buyer, but we will have to continue to wait and see, the Comapny has been very quiet lately.
Comment by blartar on Jun 17, 2016 1:14pm
I THINK they are working on their buy-out / bonus package before they agree to any sale or partnership deal . They sure don't want to leave to much on the table for us ( suckers ) I mean SHAREHOLDERS. When they get that in place, we'll hear from them in a news release. JMHO
Comment by JD2016 on Jun 17, 2016 2:12pm
Someone had said in an earlier post that based on Telesta's assets(Cash and Long Term Assets), their share price should be valued around 12 to 15 cents. Considering MCNA is valuable to a buyer, what would be a speculative price they would pay for this stock? Anyone??
Comment by Wardog14 on Jun 17, 2016 2:54pm
We've seen pricing from .10 cents a share to over a 1.00. I believe the most recent forcast suggested that a buy was possible as they had it at a low of .10 cents a share and up to a 1.00 or even a 1.10. I doubt we will come to anything close to that. It's all speculation of course. I think the majority of people thought the .30 cent range considerining its capital on hand, assets etc. It ...more  
Comment by DIprivateinvest on Jun 17, 2016 3:08pm
I think  0.25$ to 0.30 range;  I wll be happy with that. I have 500k shares bought at 0.075;  Put all my eggs in one basket; This is gambling, I know, and I get very nervous every day when no news or halt. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities